India, March 25 -- Mural Oncology plc (MURA), Tuesday announced that the ARTISTRY-7 phase 3 trial of nemvaleukin alfa in combination with Merck's (MRK) Keytruda in patients with platinum-resistant ovarian cancer will not progress to final analysis.
The decision comes as the combination treatment failed to achieve a statistically significant improvement in overall survival versus investigator's choice chemotherapy alone.
Based on this pre-specified interim analysis, the company believe that the study is highly unlikely to achieve success at the final analysis.
Meanwhile, the interim analysis of ARTISTRY-7 showed that the safety profile of nemvaleukin was generally consistent with previously reported data.
googletag.cmd.push(function() { ...